About this trial
This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).
Eligibility criteria
Qualifiers
Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or
Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles.
Disqualifiers
Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.),
History of stroke,
Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15/100),
Pain (NRS ≥ 4/10),
Trial design
Treatments tested in this trial
- Assessment of blood concentrations of microRNAs
- Chemotherapy-induced peripheral neuropathy (CIPN) - grade
- Pain assessement
- Assessment of blood concentrations of neurofilament light chain
- Neuropathic pain assessment
- Chemotherapy-induced peripheral neuropathy (CIPN) - severity